Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03728621
Other study ID # 139/2010/CE
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2012
Est. completion date June 2018

Study information

Verified date October 2018
Source University of Milan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates if promotion of a normocaloric and balanced diet and of physical activity, through an individual- or group-based lifestyle intervention of 12 months, may affect anthropometric measurements and metabolic profile in obese children.


Description:

Obese children are at risk of metabolic and cardiovascular complications both during pediatric age and later and they often show components of metabolic syndrome, such as dyslipidemia, hypertension and disturbed glucose metabolism . These complications are strictly associated with insulin resistance/hyperinsulinemia which is one of the most important contributing factors to cardiovascular disease. The gold standard technique to determine whole-body insulin sensitivity, the hyperinsulinemic-euglycemic clamp, is expensive, invasive and requires considerable expertise to be performed. Therefore, several surrogate measures have been developed. Among these, the triglyceride-glucose index (TyG) is a useful indicator, providing an easily and widely available simple laboratory method as a surrogate to estimate insulin resistance in adult, children and adolescents. Other useful indicators of insulin resistance and insulin sensitivity are the homeostatic model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check (QUICK) index, respectively, while HOMA-β% is useful to evaluate pancreatic β-cell function.

Among cardiovascular complications, obesity-related atherogenic dyslipidemia is a risk factor for cardiovascular disease. In childhood, atherogenic dyslipidemia may be associated with structural and functional vascular changes, as increased carotid intima-media thickness and increased arterial stiffness. The atherogenic index of plasma (AIP) is a recognized valuable indicator of the size of pre- and anti-atherogenic lipoprotein particle and is considered a major predictive marker of atherosclerosis risk. Additionally, it might be more promising than other lipid variables in assessing cardiovascular risk.

Guidelines for treatment of childhood obesity recommend intensive lifestyle interventions, involving diet, physical activity and behavior change, in an age-appropriate manner. While it is recognized that these interventions could favorably influence some variables of metabolic profile of obese children, no study has reported accurate possible effect on triglyceride-glucose index and atherogenic index of plasma. Furthermore, pediatric obesity interventions may be group and/or individual-based. The group-based intervention requires less resources, children may benefit from a positive social environment, but the attention to individual needs is limited, which may weaken outcomes. On the other hand, the individual-based intervention allows to tailor dietary and physical counselling on individual's needs but is more expensive and requires greater resources.

The aims of the study are to establish in patients who undergone individual versus group based intervention:

1. Effect on adiposity measured by BMI-zScore

2. effect on gluco-insulin metabolism evaluated by homa-index

3. effect on lipid profile evaluated by aterogenic index (AIP)


Recruitment information / eligibility

Status Completed
Enrollment 170
Est. completion date June 2018
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria:

- Obesity confirmed by BMI z-score >2 according to WHO growth charts

- Age at recruitment =6 years

- weight at birth =2500 g and <4000 g

- gestational age 37-42 weeks

- single birth

- Caucasian ethny

- family residing in Milan or neighborhood (=30 km)

Exclusion Criteria:

- Syndromic, organic and hormonal conditions besides obesity

- Age at recruitment <6 years

- Low birthweight (<2500 g), birthweight >4000 g

- Pre-term or post-term birth

- Twin delivery

- Other ethnies than Caucasian

Study Design


Intervention

Behavioral:
Normocaloric and balanced diet, physical activity
Promotion of normocaloric & balanced diet and physical activity

Locations

Country Name City State
Italy Ospedale San Paolo Milan

Sponsors (1)

Lead Sponsor Collaborator
University of Milan

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Height Expressed in meters 0 (t0)-12 months (t1)
Primary Blood levels of total cholesterol 0 (t0)-12 months (t1)
Primary Weight Expressed in Kilograms 0 (t0)-12 months (t1)
Primary Body Mass Index (BMI) Expressed in kg/m^2 0 (t0)-12 months (t1)
Primary Waist-to-height ratio The ratio between waist circumference (cm) and height (cm) 0 (t0)-12 months (t1)
Primary Waist circumference Expressed in cm 0 (t0)-12 months (t1)
Primary Triceps Skinfold Thickness Expressed in mm, measured with an accurate plicometer 0 (t0)-12 months (t1)
Primary Tanner Stage Classification of sexual maturation according to Tanner criteria 0 (t0)-12 months (t1)
Primary Blood levels of LDL cholesterol 0 (t0)-12 months (t1)
Primary Blood levels of HDL cholesterol 0 (t0)-12 months (t1)
Primary Blood levels of triglycerides 0 (t0)-12 months (t1)
Primary Blood levels of apolipoprotein A1 (ApoA1) 0 (t0)-12 months (t1)
Primary Blood levels of apolipoprotein B (ApoB) 0 (t0)-12 months (t1)
Primary Blood levels of insulin 0 (t0)-12 months (t1)
Primary Blood levels of glucose 0 (t0)-12 months (t1)
Primary HOmeostatic Model Assessment of Insulin Resistance (HOMA-IR) calculated as the product of fasting glucose (mmol/L) and fasting insulin (U/mL) divided by 22.5 0 (t0)-12 months (t1)
Primary QUantitative Insulin sensitivity ChecK (QUICK) index 1/[log10 fasting plasma insulin (U/mL) + log10 glucose (mg/dL)] 0 (t0)-12 months (t1)
Primary HOMA-ß% [20 fasting insulin in (U/mL)/(fasting glucose (mmol/L) - 3.5] 0 (t0)-12 months (t1)
Primary Triglyceride-Glucose index (TyG index) ln[fasting triglycerides (mg/dL) fasting glucose (mg/dL)/2] 0 (t0)-12 months (t1)
Primary Atherogenic Index of Plasma (AIP) log10 of the ratio of plasma triglycerides to HDL-cholesterol 0 (t0)-12 months (t1)
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2